Clinical outcomes of primary stenting for acute coronary syndrome based on selective use of sirolimus-eluting stents

The purpose of this study was to estimate the clinical outcomes of primary stenting for acute coronary syndrome (ACS) based on the selective use of sirolimus-eluting stents (SESs). Methods: We retrospectively estimated a consecutive 197 patients with ACS who were treated with SESs or bare metal stents (BMSs) from January 2005 to April 2006. In this period, we selectively implanted SESs for small vessel or long lesion in ACS. During the follow-up period (mean 14.5±8.3 months), major adverse cardiac events (MACE) (death, recurrent myocardial infarction [re-Mi], target lesion revascularization [TLR] and stent thrombosis [ST]) were evaluated. The incidence of MACE at one year was analyzed, comparing between the SES group (44 patients) and the BMS group (153 patients). Results: During the follow up period, there were 5 deaths. 4 re-MIs, 18 TLRs and 4 STs. The incidence of MACE at one year was 11.3%, but there was no significant difference between both groups (SES group 4.8% vs. BMS group 13.1%). Conclusion: Clinical outcomes of primary stenting for ACS based on selective use of SESs for small vessel or long lesion were acceptable.